Skip to main content
Rize RecoveryThe Newsroom
Science & Medicine· Pillar

Psychedelics & Empathogens in 2026

Psilocybin for AUD. Ibogaine for OUD. MDMA's setback. What the clinical trial landscape actually shows.

ByThe Rize NewsroomMay 8, 20261 min readPsychedelics & Empathogens

Body — 8 lenses: [Science: 5-HT2A agonism (classical psychedelics), MDMA serotonin/dopamine/NE release, ibogaine multi-receptor (anti-addiction window). Biology: acute autonomic effects, serotonin syndrome risk in combos, ibogaine cardiac risk (QT prolongation — real, requires screening), HPPD rare but possible. Psychology: “mystical experience” correlating with therapeutic outcome (Griffiths et al.); challenging experiences and how they’re handled in set/setting. Policy: mostly Schedule I; Oregon Measure 109, Colorado Prop 122, FDA breakthrough designations; MDMA 2024 rejection; state-level initiatives for decrim/regulated access. Trends: psychedelic clinic growth (often off-label ketamine), “microdosing” research (mostly null), ayahuasca tourism. Social: counterculture roots → medicalization → commercialization tension; indigenous reciprocity conversation. Treatment: psilocybin+therapy for AUD (NYU + Hopkins RCTs); ibogaine for OUD (Stanford case series, Kentucky state research); MDMA-AT for PTSD (post-2024 setback, new trials). Harm reduction: set/setting, integration, contraindications (SSRIs, heart conditions, family psychosis history for classical psychedelics), test kits.]

Sources Cited

  1. 01.A
    https://heal.nih.govNIH HEAL
  2. 02.A
    https://clinicaltrials.govClinicalTrials.gov
  3. 03.B
    https://www.maps.orgMAPS

Filed Under

sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research

Continue reading

More from this section

Science & Medicine

The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction

Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.

Science & Medicine

France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.

France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.

Science & Medicine

The FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.

DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.